Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to SGLT2 INHIBITORS

Cleveland Clinic Journal of Medicine

Long-term Empagliflozin Therapy Reduces Cardiorenal Disease Progression in Patients with Chronic Kidney Disease

Cardiology December 10th 2024

NEJM Evidence

Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds

Cardiology September 30th 2024

Annals of Internal Medicine

Sodium–Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia: A Population-Based Cohort Study

Endocrinology, Diabetes, Metabolism September 11th 2024

Annals of Internal Medicine

Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients with Stage 5 Chronic Kidney Disease

Cardiology May 8th 2024

The New England Journal of Medicine

Empagliflozin after Acute Myocardial Infarction

Cardiology April 19th 2024

Cleveland Clinic Journal of Medicine

Should I Start an SGLT-2 Inhibitor in my Patient with Heart Failure and Chronic Kidney Disease?

Cardiology April 8th 2024

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form